HEMODYNAMIC-EFFECTS OF PINDOLOL AND ATENOLOL AT REST AND DURING ISOMETRIC-EXERCISE - A NONINVASIVE STUDY WITH HEALTHY-VOLUNTEERS

被引:2
作者
RAPOLA, JM [1 ]
PELLINEN, TJ [1 ]
KOSKINEN, P [1 ]
TOIVONEN, L [1 ]
NIEMINEN, MS [1 ]
机构
[1] UNIV HELSINKI,CENT HOSP,DEPT MED 1,CARDIOVASC LAB,SF-00290 HELSINKI 29,FINLAND
关键词
atenolol; echocardiography; isometric exercise; Pindolol; systolic time intervals;
D O I
10.1007/BF01856563
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemodynamic effects of intravenous and oral pindolol and atenolol were assessed in ten healthy volunteers by left ventricular echocardiography and systolic time intervals. Measurements were made at rest and during hand-grip-induced isometric exercise. Drug doses were pindolol 0.015 mg/kg intravenously and 10 mg/day orally, atenolol 0.1 mg/kg intravenously, and 50 mg/day orally. Heart rate at rest was reduced by both drugs. The reduction caused by atenolol during oral treatment was significantly greater (p<0.01). Intravenously only pindolol reduced mean arterial pressure. During oral treatment atenolol reduced the mean arterial pressure nonsignificantly. Both drugs lowered heart rate during isometric exercise, atenolol being significantly more effective. During oral treatment atenolol blunted the heart-rate reaction to exercise. Mean arterial pressure during isometric exercise rose slightly with both drugs after intravenous administration. During oral treatment only atenolol reduced the mean arterial pressure significantly. Intravenous atenolol reduced cardiac contractility at rest, indicated by significant decreases in fractional shortening, ejection fraction, and the mean velocity of circumferential fiber shortening. In contrast, intravenous pindolol and oral therapy with either drug did not change contractility. Intravenous atenolol raised total peripheral resistance. The preejection period/left ventricular ejection time ratio decreased with intravenous pindolol, while atenolol increased it. In conclusion, atenolol had more negative inotropic and chronotropic effects, especially after acute intravenous administration. Only atenolol reduced cardiac output and increased peripheral resistance. After repeated oral administration, these effects were less apparent. © 1990 Kluwer Academic Publishers.
引用
收藏
页码:737 / 743
页数:7
相关论文
共 37 条
  • [1] Conolly M.E., Kersting F., Dollery C.T., The clinical pharmacology of beta-adrenoceptor-blocking drugs, Prog Cardiovasc Dis, 19, pp. 203-234, (1976)
  • [2] Man in't Veld A., Schalekamp M.A.D.H., Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension: The key role of vascular resistance changes in relation to partial agonist activity, J Cardiovasc Pharmacol, 5, pp. S30-S45, (1983)
  • [3] Lund-Johansen P., Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol, pindolol and bunitrolol, Eur Heart J, 4, pp. 1-12, (1983)
  • [4] Atterhog J.H., Duner H., Pernow B., Experience with pindolol, a beta receptor blocker in the treatment of hypertension, Am J Med, 60, pp. 872-876, (1976)
  • [5] Hansson L., Aberg H., Karlberg B.E., Westerlund A., Controlled study of atenolol in treatment of hypertension, Br Med J, 2, pp. 367-370, (1975)
  • [6] Waal-Manning H.J., Hypertension: Which beta-blocker?, Drugs, 12, pp. 412-441, (1976)
  • [7] Frishman W., Kostis J., Strom J., Et al., Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity, Am Heart J, 98, pp. 526-535, (1979)
  • [8] Schiess W., Welzel D., Gugler R., Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension, Eur J Clin Pharmacol, 27, pp. 529-534, (1984)
  • [9] Levy J.V., Cardiovascular effects of prinodolol (LB-46), a potent beta-adrenergic receptor antagonist, J Clin Pharmacol, 11, pp. 249-260, (1971)
  • [10] Lubawski I., Wale J., Studies with LB 46, a new beta-receptor blocking drug, Eur J Pharmacol, 6, pp. 345-348, (1969)